Quantcast

Latest placebo Stories

2014-06-27 08:24:40

CARLSBAD, Calif., June 27, 2014 /PRNewswire/ -- Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients. "Although we are announcing today the dosing of the first patient, fully one third of the patients for the study have already been qualified and are scheduled for dosing and another third are currently...

2014-06-25 08:32:39

Cognitive Deficit and Depression Symptoms Improve Significantly, Trial Data Shows GERMANTOWN, Md., June 25, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that two sets of data from the NSI-189 clinical trial in major depressive disorder (MDD) were reported at two recent academic conferences: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, on June 17th, and the International College of Neuropyschopharmacology (CINP) Annual Meeting, on June 24th, 2014....

2014-06-23 08:27:43

Gelesis100 2.25 g demonstrated significant weight loss in a double-blind, placebo-controlled, parallel-group 12-week study of overweight and obese subjects, including prediabetics BOSTON, June 23, 2014 /PRNewswire/ -- Gelesis Inc., a company focused on developing treatments for overweight and obese subjects, including prediabetics, presented today the results of a proof of concept study with its lead product, Gelesis100. In the 12-week study, 2.25 g of Gelesis100 taken twice a day...

2014-06-19 16:26:04

SAN FRANCISCO, June 19, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies - KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC). Opioids play an important role in chronic pain relief by binding to mu-receptors in the brain, but they also bind to mu-receptors in the bowel. That is why...

2014-06-19 16:25:52

LONDON, June 19, 2014 /PRNewswire/ -- AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies - KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC). Opioids play an important role in chronic pain relief by binding to mu-receptors in the brain, but they also bind to mu-receptors in the bowel. That is why patients taking opioids for chronic pain can develop OIC. In...

2014-06-19 08:28:42

BURLINGTON, ON, June 19, 2014 /CNW/ - Results from a Phase III 52 week study, show tiotropium (delivered via Respimat(®)*)5µg, a once-daily long-acting anticholinergic bronchodilator, is efficacious and well-tolerated as an add-on treatment in Japanese adults with moderate to severe symptomatic asthma, despite treatment with inhaled corticosteroids (ICS) with or without long-acting beta-2 agonist (LABA). "Even with available treatments, the extent to which patients' asthma is controlled...

2014-06-17 08:30:10

MOMENCE, Ill., June 17, 2014 /PRNewswire/ -- FutureCeuticals, Inc. today announced publication of the results of another successful human clinical study on FruiteX-B® calcium fructoborate, a patented plant mineral complex. The double-blind, placebo-controlled study examined the effects of FruiteX-B® supplementation during fourteen days on subjects with self-reported knee discomfort. The study population was equally divided between generally healthy men and women ranging in ages...

2014-06-16 08:27:34

Takeda and Lundbeck to Present Late-breaker at International College of Neuropsychopharmacology World Congress VANCOUVER, British Columbia, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced results from CONNECT, a new study that evaluated the effect of Brintellix 10-20 mg/d on aspects of cognitive function, using an objective neuropsychological test (the Digit Symbol Substitution Test or DSST) associated with executive...

2014-06-16 04:21:31

CAMBRIDGE, England, June 16, 2014 /PRNewswire/ -- Convergence Pharmaceuticals ("Convergence" or "the Company") Highlights of the data: - CNV1014802 was associated with a consistent reduction of pain severity and number of paroxysms in all primary and secondary outcomes - 2.3 unit reduction in numeric rating scale (NRS) of pain intensity compared to placebo...

2014-06-12 00:22:01

Both doses of investigational drug sarilumab met all three co-primary endpoints PARIS and TARRYTOWN, N.Y., June 12, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis (RA) patients who were inadequate responders to methotrexate (MTX) therapy. New data presented at the meeting showed that sarilumab increased major clinical...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related